International Conference on Alzheimer's and Parkinson's Diseases 2019

Lisbon, Portugal

Held in romantically beautiful Lisbon, this AD/PD was the biggest thus far, drawing 3,982 attendees from 73 countries, according to Abraham Fisher, its longtime lead organizer. But as the field grows, it has little to celebrate, and the mood reflected that. Trialists were appealing for patience and pointing to deepening clinical trials skills as they learn from continuing setbacks on investigational therapies, most recently of lanabecestat, crenezumab, and aducanumab. Trials targeting tau were not yet reading out, but the medical food Souvenaid posted modestly positive results. At the other end of the bench-to-bedside spectrum, basic science is diversifying. Next-gen genetics is spilling out gene variants which, together with RNAseq, are energizing research into glial and lipid biology. Debate about the amyloid hypothesis, a fixture at AD/PD, evolved toward a focus on genetic variability in how a person’s innate immune system responds to amyloid deposition. Aβ itself? Nothing special about it. It aggregates into an irritant as the brain’s ability to degrade it wanes with age. It starts things off, but other factors later dominate the disease. Or so researchers now think. Read Madolyn Rogers and Gabrielle Strobel’s coverage.

  1. BACE Inhibitors: Postmortem on One, Live Updates on Two
  2. Keep Your Enthusiasm? Scientists Process Brutal Trial Data
  3. Antibodies Against Microglial Receptors TREM2 and CD33 Head to Trials

GAP-Net Site Optimization Conference 2019

Nashville, Tennessee

Three years after the Global Alzheimer’s Platform (GAP) Foundation launched GAP-Net, a standing network of clinical trial sites optimized for Alzheimer’s drug studies, the group convened last month in Nashville, Tennessee, to compare notes and share best practices. With 73 sites signed on, three trials currently are up and running. What have they learned? Recruitment outreach works best at the local level, but centralizing other aspects, such as IRB approval, is helpful. Standardized contracts and rater training remain sticky issues, and sites better prepare for an onslaught of newly diagnosed early stage patients expect with upcoming Medicare changes. The mostly young audience enjoyed networking with front-line workers from other trial sites. Read Pat McCaffrey’s coverage in two parts.

View all 2 articles on this conference

International Conference on Frontotemporal Dementia 2018

Sydney, Australia

Encompassing more than half dozen subtypes, linked to at least four different protein aggregates and at least six distinct genes, frontotemporal dementia would seem like a researcher’s nightmare. And yet, its science is advancing so fast that they have never been more hopeful. Read Tom Fagan’s coverage of the 11th International Congress on FTD, held in Sydney, to catch up on the news.

View all 4 articles on this conference

PSP & CBD International Research Symposium 2018

London, England, U.K.

Tufted astrocytes? Astrocytic plaques? These tau pathologies mark progressive supranuclear palsy and corticobasal degeneration, respectively. The science of these difficult-to-diagnose diseases may finally be taking off. Read Tom Fagan’s coverage of the first PSP & CBD International Research Symposium held in London. Learn how genetics are yielding clues toward pathways, and natural history cohorts and therapeutic trials are getting underway.

View all 2 articles on this conference

Clinical Trials on Alzheimer's Disease 2018

Barcelona, Spain

When the anti-Aβ protofibril antibody Ban2401 was first shown to reduce amyloid deposition in a Phase 2b clinical trial, researchers worried. Was its otherwise exciting cognitive benefit just an artifact of an imbalance of APOE4 carriers between the treatment and placebo groups, caused by regulatory changes during the trial? At the11th Clinical Trials on Alzheimer’s Disease conference, held October 24–27 in Barcelona, investigators allayed some of those concerns. Their subgroup analysis by APOE genotype indicated that the drug effect was likely real. An early look at biomarkers suggests they are adding up toward a treatment effect on Alzheimer’s pathophysiology.

View all 10 articles on this conference